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A B S T R A C T
The aging process occurs gradually, is highly individual, with a high degree of inter and intra-individual dif-
ferences. As such, within an aging population there is significant variation in regards to extent of age related
disease and functional impairment. This variability between individuals is thought to be expressed as biological
age. Currently, the comprehensive geriatric assessment (CGA), a multidimensional, interdisciplinary diagnostic
process is used to determine an individual's medical, psychological and functional capability at older age.
However, while the CGA utilises well-established markers of physical and functional parameters, it does not
include any molecular measures that indicate an individual's biological age. Combining functional measures
with molecular markers of biological age, could improve the current CGA by identifying individuals undergoing
a rapid aging process. In this review, the current knowledge and clinical utility of potential biomarkers of aging
are presented. Although no biomarkers indicative of biological age are currently being utilized in the clinical
setting promising research advancements would suggest their application in the near future.
1. Introduction
Longevity coupled with deteriorating health has caused rising
healthcare costs and an increased pressure on health systems to manage
the growing number of older people. The high rates of in-
stitutionalization in the frail elderly lead to the development of the
comprehensive geriatric assessment (CGA) (Pilotto et al., 2017). The
CGA is a multidimensional, interdisciplinary diagnostic process that
utilises subjective and objective measures to determine the medical,
psychological and functional capabilities of older people (Pilotto et al.,
2017). This approach has facilitated the development of a coordinated,
integrated treatment plan that reduces morbidity and mortality in el-
derly populations (Pilotto et al., 2017). However, the CGA does not
currently incorporate molecular biomarkers of aging. Molecular me-
chanisms that are causally associated to the aging process and age-re-
lated diseases may be indicative of physical decline, and provide unique
insight into an individual's current and future health status.
The aging process occurs gradually and is an individual process with
a high degree of inter and intra-individual differences (Belsky et al.,
2017). For examples, some individuals with a chronological age of
85 years are physiological similar to chronologically younger in-
dividuals; while in others, physiological dysfunction may occur at a
much younger age (60 years). Even in the case of identical twins,
substantial differences in the timing of the onset of particular aging-
associated symptoms are common (Fraga et al., 2005). Over the last
decade the biological processes that contribute to aging and deterior-
ating health are being increasingly understood. In the seminal paper,
López-Otín and colleagues describe ‘The Hallmarks of Aging’ consisting
of nine overarching biological processes involved in aging in an attempt
to provide a structural framework that defines biological aging (López-
Otín et al., 2013). While these hallmarks may not be exhaustive of all
the biological processes involved in aging, they do provide a framework
around which a biological geriatric assessment (BGA) could be struc-
tured. A multidimensional BGA that couples molecular biomarkers with
targeted intervention could not only identify individuals undergoing a
rapid aging process but also allow for early, intervention and preven-
tion of age-related diseases. A BGA would complement and enhance the
current clinical CGA (Fig. 1). This targeted, individualized treatment
approach based on the underlying biology has proven to be successful
in the field of oncology, particularly in regards to tumor phenotyping
(Bournet et al., 2016).
Biomarkers can be separated into two categories; biomarkers of
exposure (risk of developing disease) and biomarkers of disease (diag-
nosis). In addition, a good clinical biomarker is usually determined by
the following criteria: 1) the biomarker is reliable and sufficiently as-
sociated with the underlying disease process 2) it's clinically practical
and 3) it guides clinical intervention (Bournet et al., 2016). However,
despite these clear criteria, few attempts to isolate molecular markers of
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aging (and associated diseases) have been undertaken. The few studies
that have investigated these markers have shown promising results. For
example, Mitnitski and colleagues assessed whether a biological frailty
index outperformed a clinical deficits frailty index in predicting mor-
tality of an aged cohort (Mitnitski et al., 2015). Interestingly, the
combined use of both the biological and clinical index of frailty (AUC
0.75) outperformed the individual models (clinical AUC: 0.71, biolo-
gical AUC: 0.66) for predicting mortality in an aged cohort (Mitnitski
et al., 2015). Thus, there is an inherent need for large cohort studies
that measure both clinical phenotype and molecular mechanisms to
determine appropriate biomarkers of the aging process. Here we review
the current evidence for the use of potential molecular biomarkers in a
geriatric assessment with particular reference to the hallmarks of aging
(López-Otín et al., 2013).
2. Aging
Social, environmental and biomedical influences in early years have
a long-term impact on health and aging. Hence, age is considered a
multi-dimensional concept that captures how people feel and function.
However, defining the operational definition of aging has proven to be
difficult with contentions over what factors should be included in this
multi-dimensional process (Cosco et al., 2014). Operational definitions
range from strictly biomedical, to strictly psychosocial highlighting life-
satisfaction and well-being as the most essential components of suc-
cessful aging. However, what is clear is that aging is a complex process
requiring more than just survival as the outcome. The CGA combines
most of the described constructs of aging (physiological, engagement,
well-being, personal resources and extrinsic factors) in its multi-di-
mensional approach to treat and manage elderly patients. Thus, the
BGA acting as a complement to this model similarly aligns with this
definition of aging but with a strong focus on the physiological com-
ponent.
3. Genomic instability
Current genomic techniques are approaching the point of being able
to detect genetic variation in people with high accuracy and at a low
cost. Given the ease of specimen attainment (blood) at first glance,
genetic testing would appear to be the most useful biomarker for as-
sessing an individual's rate of aging and physical decline. However,
only a few genetic variants (APOE and FOXO3A) have been associated
with longevity (Erikson et al., 2016; Broer et al., 2015; Fortney et al.,
2015). Approaching the aging phenomenon from a different angle
Erikson et al. demonstrated that healthy aging was associated with
reduced genetic susceptibility to Alzheimer's and coronary artery dis-
eases (CAD) (Erikson et al., 2016). Therefore, screening for the absence
of genetic susceptibility for these diseases may identify groups of in-
dividuals with a slow aging process. In addition, it should be noted that
there are documented differences in the rate of aging between popu-
lations (He et al., 2016), as such genetic markers of aging are likely to
be ethnically diverse. In addition, aging is minimally heritable (~25%)
even in environmentally homogenous populations (Christensen et al.,
2006). Furthermore, any one polymorphism usually explains only 1–8%
of an overall risk in a population and it is the additive effect of several
such factors that increases overall risk of age-related disease by 20–70%
(Ioannidis, 2003). Although there appears to be a greater genetic in-
fluence associated with centenarians (Milman and Barzilai, 2015).
Identifying the differing clusters of genes within diverse ethnic popu-
lations that contribute to the rate of aging is essential to developing
Fig. 1. A Biological Geriatric Assessment (BGA) will enhance the Comprehensive Geriatric Assessment (CGA)
A BGA could isolate individuals at risk of accelerated aging and allow for earlier clinical intervention and reduce functional.
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genetic biomarkers of aging that can be applied in a clinical setting.
4. Telomere attrition
Telomere Length (TL) is known to be inversely correlated with
chronological age and influenced by internal and external environ-
mental factors. These attributes make TL an attractive marker of bio-
logical age (Müezzinler et al., 2013) as such, it has been a target for
clinical intervention for almost two decades (Sanders and Newman,
2013). However, despite the mounting evidence indicating TL as an
accurate biomarker of biological age, the practical application remains
tenuous (Sanders and Newman, 2013). TL can oscillate within in-
dividuals at any given time point, not only as a result of aging but also
as a result of infection and environmental stress (Svenson et al., 2011).
Thus, a single time-point measure of TL may not be indicative of bio-
logical age but rather the immediate cellular environment. Several TL
measurements measured at different time points may be required to
accurately and reproducibly assess an individual's biological age. TL has
been associated with cardiovascular disease (CVD) onset and future
cardiovascular events, with individuals with shorter TL at a sig-
nificantly higher risk (25–44%) of developing CVD compared to those
with longer telomeres (Willeit et al., 2010; Brouilette et al., 2007).
However, whether telomere shortening is the cause of disease or the
consequence of the disease phenotype is not known. If shortened TL is a
consequence of the disease phenotype, then its use as a biomarker of
exposure is limited (Pooley et al., 2010). Furthermore, a recent study by
Belsky and colleagues have highlighted the complexity of the aging
process, with their finding that while the epigenetic clocks and TL can
predict biological age there is little correlation between the markers
(Belsky et al., 2016). Suggesting that different markers may reflect
different aging processes. However, this experiment was conducted
using peripheral blood, which has its own limitations reflecting human
aging mechanisms. Specimen selection when using TL as a diagnostic
biomarker is an important consideration. It is not known to what extent
TL in peripheral leukocytes (most used specimen) are representative of
TL in different organs; recent research would suggest that leukocyte TLs
are poorly correlated with TL in different tissues (Dlouha et al., 2014).
While the practicalities of TL as a diagnostic biomarker may be
questioned in regards to specimen selection, there are promising studies
that suggest TL can be targeted at a molecular level to prevent disease
onset, and slow the aging process. Pharmacological interventions in
animal models that act via altering TL have been shown to improve age-
related disease pathologies in these models (Bernardes de Jesus et al.,
2011). Thus, while current evidence would indicate that larger clinical
and cohort trials are required before a TL biomarker is ready for clinical
use, there are promising developments for therapeutic interventions to
slow the process of aging via targeting TL.
5. Epigenetic alterations
The role of epigenetics in the causation and progression of not just
age-related diseases but also the aging process, has received increasing
attention particularly at the clinical interface (Jones et al., 2015). The
underpinning theory that epigenetic modifications can be en-
vironmentally influenced and hence are theoretically reversible makes
the epigenome an attractive biomarker for determining biological age.
There are various epigenetic modifications (DNA methylation, histone
modifications, chromatin remodelling) yet, DNA methylation is the
most extensively studied. The ‘epigenetic drift’ and the ‘epigenetic
clock’ are the two phenomena that contribute to age related DNA me-
thylation (Jones et al., 2015). The ‘epigenetic drift’ refers to the ten-
dency for increasing discordance between epigenomes over time while,
the ‘epigenetic clock’ refers to specific sites in the epigenome that are
consistently related to age across individuals. Horvath and colleagues
recently used the ‘epigenetic clock’ to determine if aging rates were
influenced via ethnicity, sex and coronary heart disease (CHD). While
they report compelling evidence that epigenetic aging is associated with
ethnicity, accelerated aging was observed in Hispanic and African
American populations, a strong relationship between ‘the clock’ and
CHD risk was not observed (Horvath et al., 2016). However, recently
accelerated epigenetic age has been significantly associated with in-
creased mortality. Individuals with an accelerated age 5-years higher
than their chronological age had a 16% increase in mortality risk even
after adjusting for potential confounders (Marioni et al., 2015). Thus,
while current genome analysis may identify individuals undergoing a
slow aging process, epigenome analysis may identify individuals un-
dergoing a rapid aging process (Marioni et al., 2015). Furthermore, this
rapid aging process could be potentially reversed by non-pharmaceu-
tical interventions such as dietary and lifestyle modifications. There is
increasing evidence that dietary supplements and lifestyle modifica-
tions may influence an individual's epigenome particularly in regards to
developing cancers (Chen and Xu, 2010).
However, the clinical use of epigenome biomarkers has been ham-
pered by several methodological limitations. Firstly, the illumina 450 K
array is the current gold standard for DNA methylation however, it has
limitations in terms of genome coverage and, as such, regions of the
epigenome important to aging and age-related diseases may be being
excluded from current analysis. Secondly, analysis of different human
tissues and cells have shown tissue-specific and invariant methylation
patterns (Varley et al., 2013; Ziller et al., 2013), thus appropriate bio
specimen selection for epigenome research and the clinical application
of findings may prove to be difficult, particularly in regards to neuro
degenerative disorders. Yet, there is considerable evidence that epige-
netic age may be a more powerful predictor of declining health than
chronological age; thus large powered cross-sectional and longitudinal
human studies are required before epigenetic biomarkers can be ap-
plied in the clinic.
6. Loss of proteostasis
Efficient maintenance of the proteome is necessary for conserving
cell functionality. Protein homeostasis (proteostasis) maintains proper
cell and tissue function while impaired proteostasis is detrimental
(Kaushik and Cuervo, 2015). With age the capacity of many cells and
organs to preserve proteostasis under resting and stress conditions is
progressively compromised (Kaushik and Cuervo, 2015). A protein
biomarker of particular clinical interest for detecting biological age is
the Advanced Glycation Endproducts (AGEs) (Bürkle et al., 2015). AGEs
are formed via a non-enzymatic protein glycation posttranslational
modification termed the “Maillard Reaction”. AGEs are directly asso-
ciated with the pathophysiology of several age-related diseases
(Scheubel et al., 2006). Accumulation of AGE in vascular vessels is
linked with cardiovascular disease. In addition, skin tissue AGE can be
used to predict patient outcomes. The non-invasive measurement of
skin autofluorescence (SAF) to estimate skin tissue AGE burden is
widely established and has been shown to be an independent predictor
of cardiovascular mortality (Meerwaldt et al., 2007) and vascular col-
lagen modifications in patients graft material (Hofmann et al., 2013).
The accumulation of circulating AGEs of long lived proteins is observed
during a ‘normal’ aging process (Bürkle et al., 2015). However, while
the clinical usefulness to detect age-associated diseases is becoming
more apparent the ability of AGEs to determine biological age and a
rapid aging process has been debated, with cohort studies unable to
differentiate if AGEs reflected biological age independent of disease
(Scheubel et al., 2006). Thus, currently there is little evidence of the
clinical utility for proteome biomarkers to determine biological age,
noting there are many more biomarkers than AGEs. Findings from the
MARK-AGE study (Bürkle et al., 2015), should provide further clarity
for the clinical utility of protein biomarkers that are indicative of bio-
logical age.
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7. Deregulated nutrient sensing
It is well known that dietary needs change during the aging process.
Importantly the ability of adults to absorb and utilize nutrients is less
effective as they age (Soultoukis and Partridge, 2016). Different path-
ways that sense intracellular and extracellular levels of carbohydrates,
proteins, and lipids are coordinated at the organismal level through
hormonal signals (Soultoukis and Partridge, 2016). The capacity to
detect and respond to changes in environmental nutrient levels is es-
sential for life. As such biomarkers that could detect deregulated nu-
trient sensing would provide invaluable clinical insight. Recently,
Solon-Biet and colleagues highlighted the importance of fibroblast
growth factor 21 (FGF21) in regulating the metabolic pathways and
how its dysfunction can influence the aging process. Using mouse
models, the authors were able to show that upregulation of FGF21
caused a corresponding reduction in insulin-like growth factor-1 (IGF-
1) (Solon-Biet et al., 2016). IGF-1 is a key component of the nutrient
sensing pathways and is produced in response to growth hormone (GH)
by multiple cell types (López-Otín et al., 2013). The insulin and IGF-1
signalling (IIS) pathway is the most conserved pathway in evolution
(López-Otín et al., 2013). The decline of GH and IGF-1 secretion that
occurs as humans age is a process known as ‘somatopause’ (Junnila
et al., 2013). However, rather than being detrimental, somatopause
appears to promote longevity (Junnila et al., 2013) thus, declining GH
and IGF-1 levels maybe a protective aging mechanism. Indeed, ther-
apeutic use of GH has been associated with adverse aging outcomes
such as the onset of diabetes mellitus (Junnila et al., 2013). However,
therapeutically targeting the IIS pathway to slow the aging process has
potential. Drugs used to treat patients with acromegaly efficiently
normalize IGF-1 levels and may have anti-aging benefits. However, the
long-term use of such drugs needs to be careful study before such
medication could be used as anti-aging therapy.
8. Mitochondrial dysfunction
As initially proposed in the ‘mitochondrial theory of aging’, mi-
tochondria are involved in the aging process mainly through respiratory
dysfunction and oxidant generation (Chistiakov et al., 2014). The
theory implicates mitochondrial reactive oxygen species (ROS) as a key
component of aging. Essentially ROS is thought to induce damage to the
mitochondria and cell, resulting in tissue and organ dysfunction
(Chistiakov et al., 2014). As such, oxidative stress is a known feature of
many age-related disease pathologies such as; diabetes, CVD neurode-
generative disease, cancers and renal disease. In recent years a central
role for mitochondria (mt) DNA has been added to the ‘mitochondrial
theory of Aging’ (Chistiakov et al., 2014). Thus, mitochondrial function
as a biomarker of the aging process has been a focus of research for
many years, yet there is a noticeable lack of translation to the clinic.
This is likely caused by a number of methodological challenges in
measuring mitochondrial dysfunction. Particularly, a major challenge is
the accurate quantification of ROS as ROS has a short half-life which
influences it's stability under various storage conditions (Griendling and
FitzGerald, 2003). To circumnavigate this issue, a popular approach to
quantifying ROS is the measurement of stable by-products of oxidative
stress that have entered the circulation, however these by-products may
not accurately reflect redox stress at the cell/tissue level (Halliwell and
Whiteman, 2004). Furthermore, the specificity, sensitivity and re-
producibility of the current assays used to measure ROS are quite
variable.
In addition, to ROS mtDNA content measured as Mt/N (mitochon-
drial to nuclear genome ratio) has also been suggested as a potential
clinical biomarker of mitochondrial dysfunction (Malik and Czajka,
2013). However, like ROS inconsistency in methods used to detect,
measure and associate mtDNA biomarkers with aging have impeded the
use of these measures as molecular biomarkers.
9. Cellular senescence
Cellular senescence, the process by which cells lose the ability to
divide, is a well-established mechanism of aging and age-related dis-
eases (Childs et al., 2015). A number of aging associated senescent
biomarkers have been identified the most well-known being, β-ga-
lactosidase (β-Gal) and p16INK4a (Bernardes de Jesus and Blasco, 2012).
Notably, p16INK4a expression in skin cells has been shown to correlate
positively with chronological age; with higher number p16INK4a positive
cells observed in older individuals compared to younger individuals
(Ressler et al., 2006). In addition, lower number of p16INK4a positive
cells, have recently been associated with biological age; in individuals
enriched for familiar longevity (Waaijer et al., 2012). However, no
senescent biomarkers are currently being utilized in a clinical setting.
Interestingly, levels of p16INK4a have been compared with functional
capacity markers such as handgrip strength to determine if this mole-
cular measure is a better predictor of biological age. Despite, p16INK4a
levels showing significant associations with age and cardio/metabolic
disease the functional capacity markers were overall better predictors
of aging and cardio/metabolic disease (Waaijer et al., 2017).
In addition, to being a potential biomarker of biological age se-
nescent cells have been highlighted as a potential anti-aging ther-
apeutic target (Soto-Gamez and Demaria, 2017). Currently there are a
number of pharmaceuticals that interfere with the secretory phenotype
of senescent cells, indicating their clinical potential for suppressing
deleterious effects associated to the senescence-associated secretory
phenotype (SASP). In addition, senolytics, block survival pathways
active in senescent cells and, as such, could be an effective anti-aging
therapy. Alternatively, therapeutic interventions that bypass senes-
cence and artificially reactive proliferation of cells could enhance the
regenerative capacity of different tissues. However, the long-term ef-
fects of using such medication as anti-aging therapy is not yet under-
stood and would need to be determined before any clinical application
could be considered.
10. Altered intercellular communication
In addition to cell-autonomous alterations, aging also influences the
level of intercellular and extracellular communication (López-Otín
et al., 2013). Cell-cell communication and long-distance signalling
factors, such as, IGF-1, sex hormones and inflammatory cytokines can
all influence the local environment and contribute to the thickening of
the extra-cellular matrix associated with the aging pathology (López-
Otín et al., 2013). Of particular interest are immunological markers, as
a robust immunological memory is known to be protective in elderly
persons. Arai and colleagues found that the level of inflammation was a
better predictor of successful aging then TL in semi - (super) cen-
tenarians and that high inflammation was a significant driver of dete-
riorating health and has potential to be targeted therapeutically (Arai
et al., 2015). Given the ease of collection and measurement in-
flammatory biomarkers appear to be promising marker of biological
age. However, proving a causal relationship between these markers
particularly, the cytokines, and rapid aging has proven to be difficult
largely, due to the diverse intercellular and extracellular pathways
these molecules are involved in. However, similar to other biological
processes, determining whether a heightened inflammatory state is
pathological and detrimental to health span has proven to be difficult.
As such before inflammation can be targeted as a therapeutic option to
prevent rapid aging, the exact role inflammation plays in the aging
process needs to be elucidated.
11. Stem cell exhaustion
The decline in the regenerative potential of tissues is one of the most
obvious characteristics of aging. This decline has been attributed to
decreasing regenerative ability in tissue-specific stem cells, and stem
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cell niches. Essentially all hallmarks of aging (López-Otín et al., 2013)
have been implicated in stem cell exhaustion (Oh et al., 2014). The rate
of stem cell decline in different organ/tissue cells is likely to be in-
dicative of biological age (Oh et al., 2014). However, the true promise
of stem cell research, particularly in regards to the BGA lies in under-
standing and targeting the molecular processes controlling stem cell
survival, self-renewal, quiescence, proliferation expansion and other
such mechanisms crucial to the aging pathology. Targeting this un-
derlying pathology could lead to the development of therapies that
ultimately slow the rate of aging and potential reverse age-related
disease pathology (Oh et al., 2014). For example, protecting stem cells
from a senescent state could improve regenerative potential of an organ
or tissue. Indeed stem cell replacement therapy such as HSC trans-
plantations is already clinically utilized in the oncology fields and is an
effective cure for hematologic diseases (Copelan, 2006). Thus, there is
the potential to reverse the aging phenotype by stem cell therapy
through restorative interventions.
12. The biological geriatric assessment
Numerous biological aging models, utilising various biomarkers to
predict biological age have been published (Arbeev et al., 2016; Bae
et al., 2008; Beekman et al., 2016; Belsky et al., 2017; Cohen et al.,
2013; Levine, 2013; Martin-Ruiz et al., 2011; Mitnitski et al., 2015;
Park et al., 2009; Putin et al., 2016; Seeman et al., 2001; Seplaki et al.,
2005). However, these models of biological aging have on large sought
to determine the rate of aging in different populations and different
subgroups (Beekman et al., 2016; Belsky et al., 2017; Levine, 2013;
Park et al., 2009; Putin et al., 2016), which is not the purpose of the
BGA. The BGA aims to enhance the CGA in informing diagnostics and
intervention for patients via using markers of biological age to assist in,
improving and/or maintaining, overall patient health. As such, the
outcome measures of a successful BGA would not rely on morbidity and
mortality as in previous studies but rather on the constructs of the CGA
(physiological, engagement, well-being, personal resources and ex-
trinsic factors).
13. Conclusions
The sheer complexity of the aging process would indicate that
finding a single biomarker that identifies biological age is unlikely.
Indeed, several hallmarks of aging are likely to contribute to deterior-
ating health. Based on current evidence it would appear that there are
no clear molecular measures indicative of biological age that can be
utilized in the current geriatric evaluation. However, the importance of
combining molecular measures with confirmed markers of medical,
psychological and functional health have been, up until now, over-
looked. As such large cohort studies, combining biological markers with
medical, psychological and functional parameters are required for fu-
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